Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
Top Cited Papers
- 12 September 2006
- journal article
- review article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET)
- Vol. 58 (3), 521-590
- https://doi.org/10.1124/pr.58.3.6
Abstract
The application of pharmacogenetics holds great promise for individualized therapy. However, it has little clinical reality at present, despite many claims. The main problem is that the evidence base supporting genetic testing before therapy is weak. The pharmacology of the drugs subject to inherited variability in metabolism is often complex. Few have simple or single pathways of elimination. Some have active metabolites or enantiomers with different activities and pathways of elimination. Drug dosing is likely to be influenced only if the aggregate molar activity of all active moieties at the site of action is predictably affected by genotype or phenotype. Variation in drug concentration must be significant enough to provide “signal” over and above normal variation, and there must be a genuine concentration-effect relationship. The therapeutic index of the drug will also influence test utility. After considering all of these factors, the benefits of prospective testing need to be weighed against the costs and against other endpoints of effect. It is not surprising that few drugs satisfy these requirements. Drugs (and enzymes) for which there is a reasonable evidence base supporting genotyping or phenotyping include suxamethonium/mivacurium (butyrylcholinesterase), and azathioprine/6-mercaptopurine (thiopurine methyltransferase). Drugs for which there is a potential case for prospective testing include warfarin (CYP2C9), perhexiline (CYP2D6), and perhaps the proton pump inhibitors (CYP2C19). No other drugs have an evidence base that is sufficient to justify prospective testing at present, although some warrant further evaluation. In this review we summarize the current evidence base for pharmacogenetics in relation to drug-metabolizing enzymes.Keywords
This publication has 797 references indexed in Scilit:
- No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptylineHuman Psychopharmacology: Clinical and Experimental, 2004
- Tardive dystonia and genetic polymorphisms of cytochrome P4502D6 and dopamine D2 and D3 receptors: A preliminary findingAmerican Journal of Medical Genetics, 2002
- Extreme warfarin sensitivity in siblings associated with multiple cytochrome P450 polymorphismsAmerican Journal of Hematology, 2001
- Five Distinct Human Cytochromes Mediate Amitriptyline N‐Demethylation In Vitro: Dominance of CYP 2C19 and 3A4The Journal of Clinical Pharmacology, 1998
- A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiencyJournal of Inherited Metabolic Disease, 1996
- Preliminary phenotypic map of chromosome 4p16 based on 4p deletionsAmerican Journal of Medical Genetics, 1995
- Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapyCardiovascular Drugs and Therapy, 1990
- Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotypeJournal of Pharmacokinetics and Biopharmaceutics, 1979
- Pharmacokinetics of isoniazid metabolism in manJournal of Pharmacokinetics and Biopharmaceutics, 1976
- Abnormal reaction to procaine and succinylcholine in a patient with inherited atypical plasma cholinesterase: case reportCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 1968